Issue 14

We’ve now hit 25,000 Subscribers on PSYCH The Psychedelics Newsletter

Thank You to our global audience of investors, regulators, scientists and operators.

BUSINESS AND INVESTMENT


Awakn to Conduct Phase II Study on MDMA for Alcohol Use Disorder.


BetterLife confirms non-controlled status of 2-bromo-LSD with Health Canada.


Optimi Health receives Health Canada research exemption for psilocybin and psilocin.


Psyched Wellness completes initial data review on the medicinal potential of muscimol.


Revive collaborates with NC State to develop a biosynthetic version of psilocybin.


ATAI Life Sciences aquires majority stake in Recognify Life Sciences.


NeonMind develops protocols for its Phase 2 clinical trial using psilocybin to treat obesity.


Entheon Biomedical acquires psychedelic biotech company HaluGen Life Sciences.


Novamind expands psychedelic medicine access in Utah.


PharmaTher approved to trade in the OTCQB Venture Market.


Pure Extracts delineates study on psilocybin oral tablets, capsules and nasal gel.


Core One Labs introduces biosynthetic psilocybin to its thinstrip delivery method.


Field Trip participates in MAPs-sponsored study of MDMA therapy for eating disorders.

Feature

DAVID NUTT: THE THERAPEUTIC USE OF PSYCHEDELICS

During The PSYCH Symposium, Professor David Nutt, one of the leading figures operating in the psychedelics sector and the former Chief Drug Advisor to the British Government, delivered a keynote speech and presented an overview of the impact and potential of psychedelic medicines for society.

Enjoy this full transcription of the presentation and a selected number of video highlights.

REGULATION & LEGISLATION


Former Australian Defence Force chief supports psychedelics for mental health.


Florida lawmaker plans to introduce psilocybin-assisted-therapy legalisation bill.


Massachusetts city unanimously moves to decriminalise natural psychedelics.


Psilocybin patient hopes Canada will introduce permanent treatment regulations.


Michigan prosecutor announces his office will not pursue psychedelic cases.

SURVEY OF 1,000 ADULTS IN THE US AND UK REVEALS OVERWHELMING SUPPORT FOR PSYCHEDELIC MEDICINE LEGALISATION

Last year, PSYCH conducted an extensive survey of adults living in the US and the UK, with psychedelic medicines as the key focus on the study.

As highlighted above, the vast majority of participants believed that more research should be done on the benefits and effects of psychedelic therapies, demonstrating a strong support for the progression of research into psychedelic medicines.

To access the full findings of our study, access; The Psychedelics as Medicine Report: Second Edition, here.

RESEARCH & SCIENCE


Researchers believe psilocybin mushrooms have the potential to treat obesity.


Study shows MDMA-assisted therapy is less effective for patients who use SSRIs.


Study finds psilocybin produces changes in expression of immune-related genes in pigs.


Awakn appoints new Chief Science Officer and Head of Ketamine Alcohol Use Disorder.


The UFC looks into Johns Hopkins study on psychedelics as potential therapy for fighters.


New research on ketamine may lead to novel treatments for depression.


The Icahn School of Medicine at Mount Sinai launches a centre for psychedelics research.